Invest with Purpose

Essential News

Terumo Blood and Cell Technologies Opens Manufacturing Facility in Costa Rica

Terumo Blood and Cell Technologies Opens Manufacturing Facility in Costa Rica

  • The $60 million USD expansion demonstrates the company’s continued investment to support its global supply chain spanning 130 countries.
  • The world-class manufacturing plant will produce medical devices that collect and separate blood and cells; devices are used by global customers including blood centers, hospitals, therapeutic aphaeresis clinics, cell collection and processing organizations, researchers and private medical practices.
  • Terumo Blood and Cell Technologies will increase its production capacity of single-use blood collection supplies by 33% with its new Costa Rica site.
Cartago, Costa Rica – October 21, 2021 – Terumo Blood and Cell Technologies, a U.S.-based medical technologycompany and subsidiary of Tokyo-based Terumo Corporation, inaugurated its newest manufacturing facility in La Lima, Cartago, Costa Rica. The $60 million USD, world-class manufacturing plant aligns with the company’s mission of Contributing to Society through Healthcare and serving more patients. Production in Costa Rica at the 20,000-square-meter plant will primarily serve customers in the Americas. The company makes medical devices and products that are used to collect, separate, manufacture and process blood and cells.

Carlos Alvarado, President of the Republic of Costa Rica, recalled the life sciences multinational had announced its arrival in the country three months ago and, today, it is opening the plant. The investment will generate more employment and allow the country to continue consolidating this important productive cluster.

He stressed the Ministry of Labor, from its “EMPLEATE” initiative, has worked hand in hand with the company to benefit 78 people, investing more than ₡ 20 million, to help them develop the skills and abilities required to work there. In November, another 30 people group will start the same process. “Costa Rica, leader in medical device exports, is fertile land for sophisticated investments and for establishing long-term relationships with companies that trust us to produce high-quality products in the life sciences sector, as well as in many other fields with high levels of demand,” the mandatary concluded.

Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies, commented: “Our new world-class manufacturing site in Costa Rica is one of many strategic investments that position us for growth while broadening our geographic footprint. Costa Rica enables us to more effectively serve key markets while maintaining proximity to our healthcare customers and the patients they serve.”

Chris Williams, Senior Vice President of Global Manufacturing, added: “Costa Rica is a hub for medical device manufacturers. Here, we have available professional talent and the solid infrastructure we need to fulfill our commitment to our customers to continue delivering high-quality medical products.”

The Minister of Foreign Trade, Andrés Valenciano, was also pleased and commented: “Terumo’s expansion is an example of how the country has managed to position itself internationally as an important player and an attractive destination for this sector. It even reflects the great work that has been done to transform the country into an innovative and sophisticated hub for the health sciences field. Medical devices are the current main export product of Costa Rica, representing 35% of the country's goods exports from January to August 2021.”

In addition, he affirmed: "We celebrate the 33% expansion of Terumo's current capacity, which shows a consolidated relationship with our country, and which we hope will continue to grow and diversify its range of products according to this new investment.”

The Managing Director of CINDE, Jorge Sequeira, commented: “We are proud to have Terumo Blood and Cell Technologies in Costa Rica. Its presence attests to the country's MedTech potential and global contribution. That has been possible to Costa Rican benefits, highlighted by the company, such as the quality of our human talent and our reliable supply chain. We are a proven hub for the manufacturing and export of medical devices. For the past four years, medical devices have led the country's goods exports, which will reach a value close to US$5 billion this year. In the first semester of 2021, these exports were worth US$2.5 million. We envision a Costa Rica where more companies choose to locate here for the many value-added benefits that we offer.”

Terumo Blood and Cell Technologies employs over 7,000 people globally and maintains its headquarters in Lakewood, Colorado, in the United States. In Costa Rica, the company will employ about 700 people in 2023, when the new plant reaches full production capacity. Terumo Blood and Cell Technologies’ new facility expands the breadth of healthcare products in the life sciences sector in Costa Rica.

The new facility will include two clean rooms for medical technology assembly. It will eventually operate two shifts every day except Sunday. Interested candidates are invited to email

Made in Costa Rica by Terumo Blood and Cell Technologies
The factory in Costa Rica will support:

  • Trima Accel® Automated Blood Collection System*: A medical device used in blood banks and other healthcare settings that can collect transfusable blood components in any combination. Blood components include plasma, platelets and red blood cells.
  • Spectra Optia® Apheresis System*: An industry-leading therapeutic aphaeresis, cell processing and cell collection platform that allows operators to spend more time focusing on patient care. Among other things, this system is used for red blood cell exchanges to manage sickle cell disease and for the collection of stem cells for stem cell transplants.
  • Quantum® Cell Expansion System*: An automated cell culture system designed to reduce the operator involvement of a manual process. It utilizes hollow-fiber bioreactor technology that is functionally closed and appropriate for a Good Manufacturing Practices (GMP) environment. The Quantum system is used in the cell and gene therapy industry. This product is for laboratory use.
  • Harvest® Products*: Platelet-Rich Plasma (PRP) Procedure Pack, Bone Marrow Aspirate Concentrate (BMAC®) Procedure Pack and AdiPrep® Procedure Pack – A product line that enables the production of autologous biologics. With autologous biologics, clinicians can harness the potential of a patient’s own cells through a process of collecting and centrifugally concentrating their blood, bone marrow or adipose tissue.
*Product availability varies by geography.

About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.

Terumo Blood and Cell Technologies customers include blood centers, hospitals, therapeutic aphaeresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries.

Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. For more information, visit TERUMOBCT.COM.